Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305062 | 0.83 | RAB9A (0.41) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL14547221 | 0.82 | RAB9A (0.40) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL20910180 | 0.82 | MEN1 (0.48) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL12788604 | 0.82 | MEN1 (0.42) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL17804227 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2ANPSR1GRM5IKBKB | |
| SCHEMBL6840356 | 0.81 | MEN1 (0.45) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL9512579 | 0.81 | EGFR (0.42) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL17802041 | 0.80 | ACKR3 (0.43) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL14195506 | 0.79 | RIPK1 (0.42) | RAB9AMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL22242103 | 0.78 | HCRTR1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | RAB9A 2012/4885MEN1 4515/4885KMT2A 4151/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | RAB9A 2012/4885MEN1 4515/4885KMT2A 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.